UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038648
Receipt number R000044036
Scientific Title Analysis of EGFR mutation using highly sensitive droplet digital PCR in non-small cell lung cancer patients with EGFR mutations.
Date of disclosure of the study information 2019/11/22
Last modified on 2023/05/31 22:06:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Analysis of EGFR mutation using highly sensitive droplet digital PCR in non-small cell lung cancer patients with EGFR mutations.

Acronym

Analysis of EGFR mutation using highly sensitive droplet digital PCR in non-small cell lung cancer patients with EGFR mutations.

Scientific Title

Analysis of EGFR mutation using highly sensitive droplet digital PCR in non-small cell lung cancer patients with EGFR mutations.

Scientific Title:Acronym

Analysis of EGFR mutation using highly sensitive droplet digital PCR in non-small cell lung cancer patients with EGFR mutations.

Region

Japan


Condition

Condition

lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

Quantitative analisis of EGFR T790M mutation by highly sensitive droplet digital PCR

Basic objectives2

Others

Basic objectives -Others

We analyze quantitative EGFR T790M mutation by highly sensitive droplet digital PCR between pre and post EGFR-TKIs treatment in non-small cell lung cancer patients with EGFR mutations.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Compare the quantity of T790M clones between pre and post EGFR-TKIs treatment

Key secondary outcomes

Detection of resistant mechanism, response rate, progression free survival


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Pathologically proven non-small cell lung cancer.
2)EGFR-TKIs naive patients with relapsed disease or advance stage (III or IV).
3)EGFR mutations positive.
4)Available of tumor tissues or cytologically samples for DNA extraction.
5)Expected survival more than 90 days.
6)ECOG Performance status 0-1.
7)Meets all following laboratory data
Nt>=1000/mm3
Hb>=9.0g/dl
Plt>=10x10^4/mm3
AST, ALT<=100IU/L
T-Bil<=1.5mg/dL
Cr<=2.0mg/dL
SpO2<=90%(room air)
8)More than 20 years old on the enrollment day.
9)Patients with written informed consent.

Key exclusion criteria

1)Patients cannot ingest EGFR-TKIs.
2)Patients with paresis of intestine or ileus of intestine.
3)With chronic diarrhea.
4)Interstitial pulmonary disease, drug-induced interstitial pulmonary disease and irradiation pneumonitis clearly detected by chest CT.
5)Uncontrollable pleural/ abdominal/ pericardial effusion.
6)Symptomatic brain metastasis required for radiation therapy or surgical resection.
7)Patients with a radiation therapy included lung field within 28 days before enrollment.
8)Active infection to need systemic treatment.
9)Patients with severe complications (bleeding of digestive tract, heart disease, glaucoma, diabetes, etc.).
10)Patients who are different for the participation in the study by complication of mental disease or psychiatric symptom.
11)Patients with pregnant or possibly pregnant, nursing.
12)Any other patients regarded as unsuitable for this study by the investigators.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Shhinnosuke
Middle name
Last name Takemoto

Organization

Nagasaki University Hospital

Division name

Department of Respiratory Medicine

Zip code

852-8501

Address

1-7-1 Sakamoto, Nagasaki, Japan

TEL

095-819-7273

Email

shinnosuke-takemoto@umin.ac.jp


Public contact

Name of contact person

1st name Shinnosuke
Middle name
Last name Takemoto

Organization

Nagasaki University Hospital

Division name

Department of Respiratory Medicine

Zip code

852-8501

Address

1-7-1 Sakamoto, Nagasaki, Japan

TEL

095-819-7273

Homepage URL


Email

shinnosuke-tgakemoto@umin.ac.jp


Sponsor or person

Institute

Nagasaki University Hospital

Institute

Department

Personal name



Funding Source

Organization

Nippon Boehringer Ingelheim Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nagasaki University Hospital

Address

1-7-1 Sakamoto, Nagasaki, Japan

Tel

095-819-7726

Email

gaibushikin@ml.nagasaki-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

長崎大学病院


Other administrative information

Date of disclosure of the study information

2019 Year 11 Month 22 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

5

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2019 Year 11 Month 21 Day

Date of IRB

2019 Year 11 Month 19 Day

Anticipated trial start date

2019 Year 12 Month 01 Day

Last follow-up date

2022 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

none


Management information

Registered date

2019 Year 11 Month 20 Day

Last modified on

2023 Year 05 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044036


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name